
Releases
Halozyme Projects Minimal Medicare Royalty Impact Through 2035
San Diego-based Halozyme Therapeutics confirmed it expects zero to minimal impact on its royalty revenues through at least 2035 following an internal review of the latest draft Medicare Drug Price Negotiation Program rules. The company maintains that its core business model remains insulated from the proposed federal regulatory changes.



























